Summary
Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.
In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Edwards MS, Levin VA, Wilson CB (1980) Brain tumour chemotherapy evaluation of agents in current use for phase II and III trials. Cancer Treat Rep 64: 1179–1205
Di Marco A (1975) Adriamycin (NSC-123127): Mode and mechanism of action. Cancer Chemother Rep Part III 6: 91–106
Benjamin RS, Wiernek PH, Bachur NR (1974) Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule. Cancer 33: 19–27
Boustelle CT, Uari SH, Rekate H (1983) Intracarotid chemotherapy of glioblastomas after induced blood-brain barrier disruption. AJNR 4 (3): 810–812
Nakazawa S, Itoh Y (1983) New management of brain neoplasms: Local injection of Adriamycin. No Shinkei Geko 11 (8): 821–827
Peterson C, Paul C, Gahrton G (1981) Anthracycline-DNA complexes as slow release preparations in the treatment of acute leukemia. In: Lewis DH (ed) Controlled release of pesticides and pharmaceuticals. Plenum Publishing Corporation, New York, pp 49–65
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275
Sakai N, Kondo H, Shikinami A, Hirata T, Funakoshi T, Tanabe Y, Yamada H (1984) Postoperative treatment for malignant intracranial tumours —especially concerning intermittent intracarotid administration of Adriamycin (in Japanese). No Shinkei Geko 12: 237–243
Peterson C, Gunvén P, Theve NO (1986) Comparative pharmacokinetics of doxorubicin and epirubicin in patients with gastrointestinal cancer. Cancer Treat Rep 70: 947–952
Pastan I, Gottesman M (1987) Multiple-drug resistance in human cancer. N Engl J Med 316: 1388–1393
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
von Holst, H., Knochenhauer, E., Blomgren, H. et al. Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta neurochir 104, 13–16 (1990). https://doi.org/10.1007/BF01842886
Issue Date:
DOI: https://doi.org/10.1007/BF01842886